Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism?

Please use this identifier to cite or link to this item: http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/378

Full metadata record

DC Field	Value	Language
dc.contributor.author	Garcia, David A.	-
dc.contributor.author	Lim, Wendy	-
dc.date.accessioned	2015-11-30T04:12:05Z	-
dc.date.available	2015-11-30T04:12:05Z	-
dc.date.issued	2013	-
dc.identifier.uri	http://220.231.117.85:8000/handle/DHKTYTHD_123/378	-
dc.description.abstract	A 44-year-old otherwise healthy woman has completed 3 months of anticoagulation therapy for a first episode of unprovoked pulmonary embolism. At the time of diagnosis and before the initiation of anticoagulation, she was found to have an elevated IgG anticardiolipin antibody (ACLA), which was measured at 42 IgG phospholipid (GPL) units (reference range, 15 GPL units) with negative lupus anticoagulant (LAC) testing. Should this laboratory finding affect the recommended duration of anticoagulant therapy?	vi
dc.language.iso	en	vi
dc.publisher	American Society of Hematology	vi
dc.title	Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism?	vi
dc.type	Article	vi
Appears in Collections	Huyết học = Hematology

Files in This Item:

File	Description	Size	Format
Hematology-2013-Garcia-681-3.pdf Restricted Access		302.19 kB	Adobe PDF	Request Item